Ascendis Pharma Files Routine 6-K Disclosure

Ticker: ASND · Form: 6-K · Filed: Apr 9, 2025 · CIK: 1612042

Sentiment: neutral

Topics: sec-filing, 6-k, routine-disclosure

Related Tickers: ASND

TL;DR

Ascendis Pharma (ASND) filed a 6-K, standard SEC disclosure, no major news.

AI Summary

Ascendis Pharma A/S filed a Form 6-K on April 9, 2025, to report information as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure to the SEC.

Why It Matters

This filing indicates Ascendis Pharma A/S is fulfilling its ongoing reporting obligations as a foreign private issuer with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not contain new material information that would typically impact risk.

Key Players & Entities

FAQ

What type of filing is Ascendis Pharma A/S submitting?

Ascendis Pharma A/S is submitting a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What is the filing date of this Form 6-K?

This Form 6-K was filed on April 9, 2025.

What is the principal executive office address for Ascendis Pharma A/S?

The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.

Does Ascendis Pharma A/S file annual reports under Form 20-F or 40-F?

Ascendis Pharma A/S files annual reports under Form 20-F.

What registration numbers are mentioned in the incorporation by reference section?

The registration numbers mentioned are 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, and 333-228576, all on Form S-8.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 9, 2025 regarding Ascendis Pharma A/S (ASND).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing